Targeting the Undruggable: Deep Learning-Driven Design of Peptide Therapeutics in Cancer
Pharmaceuticals · 27.06.2026 · 19 (7) · 998
DOI: 10.3390/ph19070998 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 27.06.2026. Verfasst von Ha Thi Ngoc Nguyen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, Lac Hong University, Dong Nai 810000, Vietnam. Die Arbeit nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The majority of disease-associated proteins are considered “undruggable” due to the absence of well-defined binding pockets, the presence of extended interaction surfaces, and intrinsic structural disorder, which collectively limit the effectiveness of conventional small molecules and biologics. Representative examples include KRAS, p53, and c-MYC. Peptide therapeutics, particularly macrocyclic peptides, occupy a unique chemical space capable of targeting such recalcitrant protein–protein interactions (PPIs) where small molecules often fail. However, traditional peptide discovery, which relies heavily on high-throughput screening, is labor-intensive and frequently yields candidates with suboptimal pharmacological properties. The integration of artificial intelligence has begun to transform peptide discovery from a largely empirical process into a rational and design-driven paradigm. Modern deep learning approaches, including diffusion-based generative models, enable the de novo design of peptide binders with high affinity and structural precision, even for disordered or previously intractable targets. In this perspective, we highlight key structural and biological challenges associated with undruggable proteins and consider how peptide-based modalities are beginning to overcome these longstanding barriers. We further explore how advances in artificial intelligence and computational modeling may reshape the rational design of next-generation peptide therapeutics and propose an integrated experimental–computational framework to facilitate the development of clinically actionable candidates.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Pharmacy, Lac Hong University, Dong Nai 810000, Vietnam.
- College of Pharmacy, Dongguk University, Seoul 04620, Republic of Korea.
- Department of Physiology, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea.
- Vinmec-VinUni Institute of Immunology, Vin University, Hanoi 100000, Vietnam.
ORCID-Profile: Ha Thi Ngoc Nguyen, Nhung Thi Hong Van, Minh Tuan Nguyen
Zitieren
APA
Nguyen, H. T. N., Le, B. H. N., Van, N. T. H., Tran, T. T. T., & Nguyen, M. T. (2026). Targeting the Undruggable: Deep Learning-Driven Design of Peptide Therapeutics in Cancer. Pharmaceuticals, 19(7), 998. https://doi.org/10.3390/ph19070998
Vancouver
Nguyen HTN, Le BHN, Van NTH, Tran TTT, Nguyen MT. Targeting the Undruggable: Deep Learning-Driven Design of Peptide Therapeutics in Cancer. Pharmaceuticals. 2026;19(7):998. doi:10.3390/ph19070998
BibTeX
@article{Nguyen2026,
author = {Nguyen, Ha Thi Ngoc and Le, Bao Hong Ngoc and Van, Nhung Thi Hong and Tran, Trinh Thi Tuyet and Nguyen, Minh Tuan},
title = {Targeting the Undruggable: Deep Learning-Driven Design of Peptide Therapeutics in Cancer},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {7},
pages = {998},
doi = {10.3390/ph19070998}
}
EUVIMED